ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic he… Read more
ViroGates A/S (VIRO) - Total Liabilities
Latest total liabilities as of September 2025: Dkr11.38 Million DKK
Based on the latest financial reports, ViroGates A/S (VIRO) has total liabilities worth Dkr11.38 Million DKK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ViroGates A/S - Total Liabilities Trend (2015–2024)
This chart illustrates how ViroGates A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ViroGates A/S Competitors by Total Liabilities
The table below lists competitors of ViroGates A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AMEN Properties Inc
PINK:AMEN
|
USA | $1.06 Million |
|
Blackbird Critical Metals Corp
OTCQB:BBCMF
|
USA | $54.69K |
|
White Energy Company Limited
PINK:WECFF
|
USA | $56.69 Million |
|
Techcential International Ltd
TWO:6616
|
Taiwan | NT$319.18 Million |
|
Paranapanema S.A
SA:PMAM3
|
Brazil | R$8.22 Billion |
|
Smart Gunes Enerjisi Teknolojileri Arastirma Gelistirme Uretim Sanayi ve Ticaret
IS:SMRTG
|
Turkey | TL18.13 Billion |
|
Chia Yi Steel Co Ltd
TWO:2067
|
Taiwan | NT$1.60 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down ViroGates A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ViroGates A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ViroGates A/S (2015–2024)
The table below shows the annual total liabilities of ViroGates A/S from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr6.87 Million | -9.05% |
| 2023-12-31 | Dkr7.55 Million | +420.19% |
| 2022-12-31 | Dkr1.45 Million | -61.85% |
| 2021-12-31 | Dkr3.80 Million | -45.14% |
| 2020-12-31 | Dkr6.93 Million | +135.62% |
| 2019-12-31 | Dkr2.94 Million | +21.97% |
| 2018-12-31 | Dkr2.41 Million | +21.76% |
| 2017-12-31 | Dkr1.98 Million | -34.23% |
| 2016-12-31 | Dkr3.01 Million | -0.46% |
| 2015-12-31 | Dkr3.03 Million | -- |